MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA Type-c)
Also known as: MOTS-c, MOTSc, Mitochondrial ORF of 12S rRNA type-c
Prompted by Jack Butcher (Visualize Value) · AI-authored by Claude · Research-sourced
A mitochondrial-derived peptide that activates AMPK and acts as an exercise mimetic. Improves insulin sensitivity and metabolic homeostasis, with levels declining significantly with age.
Quick Facts
Research compound only. Not approved for human therapeutic use in any country. All data is preclinical. Discovered by Dr. Changhan David Lee at the University of Southern California.
Overview
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA Type-c) is a 16-amino acid peptide encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Dr. Changhan David Lee and colleagues at the USC Leonard Davis School of Gerontology, MOTS-c is the second major mitochondrial-derived peptide (MDP) identified after Humanin.
MOTS-c functions as an exercise mimetic and metabolic regulator, representing a remarkable finding: the mitochondrial genome — traditionally viewed as encoding only structural components of the electron transport chain — produces signaling peptides that regulate whole-body metabolism.
The peptide activates AMPK (AMP-activated protein kinase), the master cellular energy sensor, and promotes metabolic homeostasis. In animal models, MOTS-c improves insulin sensitivity, prevents age-related and diet-induced obesity, and enhances exercise capacity. Circulating MOTS-c levels increase during exercise and decline with age, suggesting it mediates some of the metabolic benefits of physical activity.
MOTS-c is unique among MDPs in that it translocates to the nucleus during metabolic stress, where it directly regulates gene expression through interaction with ARE (antioxidant response element) motifs — establishing a direct mitochondria-to-nuclear signaling axis.
Mechanism of Action
MOTS-c activates AMPK (AMP-activated protein kinase) through modulation of the folate cycle and de novo purine biosynthesis pathway. Specifically, MOTS-c inhibits the folate cycle enzyme methylenetetrahydrofolate dehydrogenase (MTHFD), which leads to accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) — a known endogenous AMPK activator.
AMPK activation by MOTS-c triggers a cascade of metabolic effects: enhanced glucose uptake independent of insulin, increased fatty acid oxidation, improved mitochondrial biogenesis through PGC-1alpha activation, and suppression of lipogenic gene expression. These effects collectively improve metabolic homeostasis.
During metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus — a remarkable behavior for a mitochondrial-derived peptide. In the nucleus, MOTS-c interacts with ARE (antioxidant response element) motifs and regulates the expression of genes involved in glucose and lipid metabolism, antioxidant defense, and cellular stress responses. This nuclear translocation establishes a direct communication pathway from mitochondria to nuclear gene regulation.
MOTS-c also enhances skeletal muscle glucose metabolism through GLUT4 translocation to the cell membrane, improving glucose uptake in a mechanism analogous to both insulin signaling and exercise-induced glucose transport.
The peptide modulates the NAD+/NADH ratio, contributing to sirtuin activation and broader metabolic regulation. It reduces endoplasmic reticulum stress and inflammatory signaling, connecting metabolic improvement to anti-inflammatory effects.
Research Summary
The discovery paper by Lee et al. (2015) established MOTS-c as a mitochondrial-derived peptide that regulates insulin sensitivity and metabolic homeostasis. Mice treated with MOTS-c were protected against age-dependent and high-fat diet-induced insulin resistance and obesity.
Exercise biology research revealed that MOTS-c levels increase in skeletal muscle and plasma during acute exercise in both mice and humans. This discovery positioned MOTS-c as a potential molecular mediator of exercise's metabolic benefits — an "exercise mimetic" encoded in the mitochondrial genome.
Aging studies showed that circulating MOTS-c levels decline with age in both mice and humans. Japanese centenarians were found to carry a specific mitochondrial DNA variant (m.1382A>C) that produces a more stable MOTS-c variant, suggesting evolutionary selection for enhanced MOTS-c signaling in long-lived populations.
Nuclear translocation studies (Kim et al., 2018) demonstrated that MOTS-c moves to the nucleus during metabolic stress and glucose restriction, where it regulates ARE-containing gene expression. This was a groundbreaking finding showing direct mitochondria-to-nuclear retrograde signaling via a peptide.
Obesity and diabetes research in diet-induced obese mice showed that MOTS-c treatment improved glucose tolerance, reduced fat mass, and enhanced insulin sensitivity without changes in food intake — suggesting metabolic rate enhancement rather than appetite suppression.
Limitations: All data is preclinical. No human interventional trials have been conducted. The peptide's pharmacokinetics in humans are not characterized. Optimal dosing, route, and duration for human use are unknown.
Key References
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Lee C, Zeng J, Drew BG, et al. · Cell Metabolism (2015) · 10.1016/j.cmet.2015.02.009
The discovery paper establishing MOTS-c as a mitochondrial-derived peptide that regulates metabolic homeostasis. Demonstrated that MOTS-c treatment prevents obesity and insulin resistance in mice.
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Reynolds JC, et al. · Nature Communications (2021) · 10.1038/s41467-020-20790-0
Showed that MOTS-c levels increase with exercise, decline with age, and that MOTS-c treatment in aged mice improves physical capacity and skeletal muscle homeostasis, establishing it as an exercise mimetic.
Mitochondrial-derived peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress
Kim KH, Son JM, Benayoun BA, Lee C. · Cell Metabolism (2018) · 10.1016/j.cmet.2018.06.008
Groundbreaking study demonstrating that MOTS-c translocates from the cytoplasm to the nucleus during metabolic stress, where it binds ARE motifs to regulate gene expression — establishing direct mitochondria-to-nuclear communication.
A mitochondrial-encoded MOTS-c variant correlates with exceptional longevity in the Japanese population
Fuku N, et al. · Aging Cell (2015) · 10.1111/acel.12405
Identified a mitochondrial DNA variant producing a more stable MOTS-c in Japanese centenarians, suggesting that enhanced MOTS-c signaling contributes to exceptional human longevity.
Protocols
Metabolic optimization / exercise mimetic (research community)
No established human dosing. Community doses are extrapolated from rodent studies (5–15 mg/kg IP in mice). Morning dosing is theoretically preferred to align with metabolic rhythms. Often discussed alongside exercise and fasting protocols.
Animal research reference
Standard dosing range from published rodent studies. The Lee et al. (2015) discovery paper used 5 mg/kg IP. Higher doses up to 15 mg/kg have been used in obesity and exercise studies. These are animal research parameters.
Side Effects & Safety
| Frequency | Effect |
|---|---|
| common | Injection site reaction Mild local irritation, redness, or discomfort at the subcutaneous injection site. |
| uncommon | Hypoglycemia MOTS-c enhances glucose uptake and insulin sensitivity. Individuals on diabetes medications or in a fasted state should monitor blood glucose. |
| uncommon | Gastrointestinal discomfort Mild nausea or digestive changes reported anecdotally. May relate to metabolic shifts. |
| uncommon | Fatigue or energy fluctuation Some users report transient fatigue as metabolic pathways adjust. Others report increased energy. Individual responses vary. |
Contraindications
- —Type 1 diabetes or insulin-dependent diabetes (risk of hypoglycemia with enhanced glucose uptake)
- —Pregnancy or breastfeeding (no safety data)
- —Active cancer (AMPK activation has complex, context-dependent effects on tumor biology)
- —Concurrent use of metformin or other AMPK activators (potential additive effects)
Interactions
- —Metformin (both activate AMPK — potential additive effects on glucose metabolism)
- —Insulin and sulfonylureas (enhanced insulin sensitivity may increase hypoglycemia risk)
- —AICAR or other AMPK activators (additive pathway activation)
- —Folate supplements (MOTS-c modulates the folate cycle — potential interaction)
Reconstitution & Storage
Related Peptides
MOTS-c and Humanin are both mitochondrial-derived peptides but serve distinct roles — MOTS-c is primarily a metabolic regulator (AMPK activation, exercise mimetic) while Humanin is cytoprotective (anti-apoptotic, neuroprotective). SS-31 targets mitochondrial membrane structure. For metabolic goals, MOTS-c shares mechanistic overlap with semaglutide (both improve insulin sensitivity) but through entirely different pathways.